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ABSTRACT
BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors 
(MEKi) were recently approved for therapy of metastatic melanomas harbouring the 
oncogenic BRAFV600 mutation. Although these therapies have shown pronounced 
therapeutic efficacy, the limited durability of the response indicates an acquired 
drug resistance that still remains mechanistically poorly understood at the molecular 
level. We conducted transcriptome gene profiling in BRAFi-treated melanoma cells 
and identified that Mer tyrosine kinase (MerTK) is specifically upregulated. MerTK 
overexpression was demonstrated not only in melanomas resistant to BRAFi 
monotherapy (5 out of 10 samples from melanoma patients) but also in melanoma 
resistant to BRAFi+MEKi (1 out of 3), although MEKi alone does not affect MerTK. 
Mechanistically, BRAFi-induced activation of Zeb2 stimulates MerTK in BRAFV600 
melanoma through mTORC1-triggered activation of autophagy. Co-targeting MerTK 
and BRAFV600 significantly reduced tumour burden in xenografted mice, which was 
pheno-copied by co-inhibition of autophagy and mutant BRAFV600.
INTRODUCTION
Melanoma is one of only three aggressive 
cancers whose incidence and mortality have increased 
continuously over the past two decades [1]. Compared 
with the commonly used chemotherapeutic agent 
dacarbazine, treatment with a BRAFi or a BRAFi/MEKi 
combination results in improved overall survival of 
patients with metastatic melanoma carrying mutant BRAF 
[2-5]. However, the durability of response is limited 
[6] and tumour progression occurs after 6-7 months 
of monotherapy or around 9 months of combination 
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therapy, indicating the development of compensatory 
mechanisms that antagonize mutant BRAF and MEK 
inhibition. When bypassing BRAFV600E activity, resistant 
melanomas often exhibit reactivation of the interconnected 
MAPK and PI3K/Akt axes, associated with BRAF-
independent reactivation of MAPK [7] (caused in some 
cases by enhanced CRAF [8]), elevated PDGFR [9], 
and remodeling of the cancer stroma [10]. However, the 
molecular mechanisms of resistance are not yet fully 
understood and need further investigation. 
Autophagy is a conserved intracellular degradation 
system that is well known to be activated downstream 
of mTORC1 [11, 12]. Enhanced autophagic activity is 
required for energy metabolism during development. 
Upon nutrient withdrawal, newborn mice die within one 
day if autophagic activity is inhibited [13], indicating a 
pivotal role for autophagy in response to stress cues. 
Indeed, autophagic activity is elevated in different types 
of cancer and is considered a therapeutic target in several 
clinical trials [14, 15]. Nevertheless, the role of autophagy 
in tumor development and progression is controversial, 
since a range of studies has hinted at a role of autophagy in 
promoting apoptosis [16, 17]. These observations support 
the concept of context-dependent regulatory mechanisms 
of autophagy during cancer progression [18], possibly 
through differential regulation of distinct, yet unknown, 
downstream targets. To dissect the underlying molecular 
mechanisms of adapted reactivation of the RTK/MAPK 
signaling in response to BRAF and combined BRAF/MEK 
inhibition, we conducted transcriptome gene profiling 
in vemurafenib-treated melanoma cells. We focused 
on proto-oncogenes encoding kinases that are often 
hyperactivated in cancers. We confirmed the results in cell 
lines and clinical melanoma samples that are resistant to 
BRAFi and BRAFi/MEKi. 
Here we show that BRAFi induces upregulation 
of MerTK, a master regulator of phagocytosis, which 
contributes to acquired resistance to BRAF inhibition in 
BRAFV600E melanoma. Our data identify MerTK as a novel 
mediator of cancer cell survival driven by mTORC1/
autophagy signaling, and suggest that combinatorial 
inhibition of BRAFV600E and the autophagy/MerTK axis 
provides a novel therapeutic strategy to overcome acquired 
resistance to BRAFi or BRAFi/MEKi in melanoma 
patients.
RESULTS
MerTK is over-expressed in human melanomas 
with acquired resistance to vemurafenib
To investigate RTK-associated genes that impact 
on the relief of BRAFV600E inhibition, we performed 
transcriptome screening of BRAFV600E melanoma cells 
treated with PLX4720, the precursor of vemurafenib 
(PLX4032) with equivalent action mode [19], for 3 days. 
Upon completion of therapy, ERK phosphorylation was 
restored. Gene expression profiling revealed significant 
upregulation of 95 kinase-encoding genes. The most 
prominent was MERTK (Figure 1A). Transcriptional 
upregulation of MERTK and several other genes including 
CMPK2, PIK3R1, PROS1 and AXL was confirmed by 
quantitative PCR (qPCR, Supplementary Figure S1A). 
Therapy-induced overexpression of MerTK on the plasma 
membrane (Supplementary Figure S1B) was dependent of 
the time-course and occurred after 48 hours of BRAFi-
treatment in 50% (8 out of 16) of the examined BRAF 
mutant human melanoma cell lines (Figures 1B, S1C 
and S1D). Similarly, MerTK expression could also be 
regulated in a dose-dependent manner (Supplementary 
Figure S1E). BRAFi-triggered MerTK overexpression was 
specific for melanoma cells carrying a BRAFV600 mutation 
but was not observed in the majority of BRAF wild-type 
cells (Supplementary Figure S1F). Interestingly, the 
upregulation of MerTK was often associated with restored 
ERK phosphorylation post-vemurafenib treatment. Indeed, 
overexpressed MerTK strongly enhanced its tyrosine 
phosphorylation, indicating a functional MerTK signaling 
transduction that might be switched on (Supplementary 
Figure S1G). MerTK was recently proposed as a potential 
therapeutic target in melanoma [20]. Compared with 
untreated human melanomas, increased expression of 
MerTK was detected in the tumours from vemurafenib-
treated patients (Figures 1C, S1H). More importantly, in a 
comparison between pre- and post-therapy of vemurafenib 
in the same patient (paired samples), significantly 
higher MerTK levels were detected in the new lesions 
after therapy in 50% (5 out of 10) of the patients with 
clinically diagnosed acquired resistance (Figures 1D, S1I). 
Moreover, although melanoma cell lines resistant to single-
agent MEKi did not upregulate MerTK (Supplementary 
Figure S1J), ~30% (1 out of 3) paired human melanomas 
with acquired resistance to combined BRAFi+MEKi 
therapy showed elevated MerTK expression (Figures 1E, 
supplemental Table S2.1). Basal MerTK was exclusively 
detected in melanomas but not in benign melanocytic nevi 
(Supplementary Figure S1K). These observations imply 
a potential role of MerTK in supporting cell survival in 
malignant melanoma in response to stress. 
MerTK promotes melanoma cell survival and 
colony formation in response to BRAFi
Resistance against BRAFi develops rapidly 
in melanoma patients and is characterized by ERK 
reactivation that promotes cancer cell proliferation and 
induces a protective response to stress [21]. To investigate 
whether vemurafenib-elicited MerTK upregulation leads 
to restoration of proliferation in resistant cell populations, 
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Figure 1: Vemurafenib triggers oncogenic MerTK upregulation in BRAFV600E melanoma cells. A., Transcriptome profiling 
of deregulated kinase-coding genes in melanoma cells treated with vemurafenib (1 μM) for 3 days. 95 kinase-coding genes with significant 
change (cutoff: P = 0.05, linFC = 1.5, average expression = 4) are presented. The red arrow points at the top three genes with highest 
enrichment. B., A375p and A2058 melanoma cells were treated with 1 μM vemurafenib or dabrafenib and MerTK expression was 
monitored at the given time-points. The impact on MAPK signaling was determined by the status of pERK (See also Figures S1C, S1D, 
S1E). C., MerTK expression was examined in 10 human melanomas with pre-/post-vemurafenib therapy (5 of each, unpaired samples; 
uncropped gel see Figure S1H). 60 μg of total protein was loaded per well. The code of each sample was provided by the University hospital 
of Zurich. D., Endogenous MerTK expression level was monitored in 2 melanoma patients with pre-/post-vemurafenib therapy (paired 
samples, diagnosed as resistant melanomas to vemurafenib in clinic) by IHC (See also Figure S1I). The code of each tumor (up-right) was 
provided by the Papa Giovanni XXIII Hospital (for retrospective study) and the host tissue/organ was indicated (down-left). Purple staining 
indicates MerTK and light/dark brown indicates melanin (patient 4). Under vemurafenib therapy, patient 4 developed a metastatic tumor 
(I13-192971E1) of the soft tissue (pathological scoring is shown in supplemental table S2.1 and the clinical characteristics of the patients 
are shown in supplemental table S2.2). E., Melanoma cells were isolated from Z1 and Z2 melanomas resistant to BRAFi+MEKi therapy. 
The isolated cancer cells were cultured for one week and total protein was extracted for western blotting analysis. A375R cell line was used 
as a control for MerTK upregulation.
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we generated resistant melanoma cell lines A375R and 
A2058R that were exposed to BRAFi for 2 months. 
Interestingly, both A375p and A2058 cells underwent 
continuous morphological change during the treatment. 
Short-term treatment for 6 days resulted in filopodia-like 
membrane protrusions with increased actin bundling and 
enhanced spindle-shaped morphology (Supplementary 
Figure S2A, white arrow), but the cells gradually 
became flat (Supplementary Figure S2A, A375R and 
A2058R) when they lost responsiveness to BRAFi [22] in 
association with increased MerTK level (Supplementary 
Figure S2A, red stars). Although the proliferation of PLX-
treated cells in vitro was restrained when compared with 
DMSO treatment, the invasive potential was significantly 
increased in a matrigel-based 3D invasion assay 
(Supplementary Figure S2B). In fact, untreated A375p 
cells tended to form aggregates on matrigel, whereas 
A375R cells were much flatter, displayed individual 
migratory patterns (Supplementary Figure S2C) and 
exhibited elevated invasiveness (Supplementary Figure 
S2D). Notably, MerTK was stably maintained in both 
resistant cell lines in association with restored ERK and 
Akt phosphorylation, increased myosin phosphorylation 
and enhanced expression of fibronectin, the key regulators 
of cancer cell invasion (Supplementary Figure S2E) [23]. 
To evaluate the role of MerTK in this phenotype, we 
decided to study the behavior of the cells upon genetic 
depletion of MERTK. Knockdown of MERTK with three 
different shRNAs led to a similar phenotype in A2058 
melanoma cells (constitutively expressing MerTK) grown 
on matrigel (Supplementary Figure S2F), although cell 
proliferation was not affected (Supplementary Figure 
S2G). However, when incubated with PLX, the colony 
formation was severely impaired in three different 
MERTK-depleted melanoma cell lines A375p, A2058 and 
SKMel100 (Figures 2A, Supplementary Figure S2H), all 
of which were associated with an increased pro-apoptotic 
potential (Figure 2B). Consistently, loss of MerTK 
sensitized melanoma cells to apoptosis upon BRAF 
inhibition, as determined by increased accumulation of 
cleaved Caspase 3 (Figure 2C), suggesting that MerTK 
is a critical mediator regulating cellular responses in 
order to antagonize apoptotic stress. This finding was 
further supported in a xenograft mouse model in which 
initial tumour formation was significantly delayed after a 
decrease in MerTK (Figure 2D), although these tumours 
relapsed later (Figure 2E).
MerTK is stringently regulated by the autophagic 
signaling pathway
MerTK is a member of the RTK family TAM 
(consisting of Tyro3, Axl and Mer), whose regulatory 
signaling is still poorly understood [24]. We analyzed 
the microarray data to compare signaling pathways 
co-activated with MerTK, and found that p85, the 
regulatory subunit of PI3K was elevated together with 
a moderate increase of mTOR, which was consistent 
with the observation of enhanced Akt phosphorylation 
(Supplementary Figure S2E). Therefore, we hypothesized 
that the mTOR/PI3K/Akt pathway might be affected 
upon BRAFi treatment. In addition, as MerTK is 
critical for macrophage engulfment, we examined the 
same microarray data for the signaling events related 
to endocytosis/phagocytosis. Interestingly, autophagy, 
a conserved lysosomal degradation machinery acting in 
response to nutrient deprivation and pathological stress 
[12], appeared to be enhanced. This was suggested by the 
simultaneous increase of two essential activators, ATG2B 
and ATG4A in two examined cell lines (Supplementary 
Figure S3A). Other factors important in the maintenance 
of autophagic activity, including ULK1 and ATG7, 
were also increased at the mRNA level (Supplementary 
Figure S3A). Consistently, PLX treatment promoted the 
cleavage of microtubule-associated protein 1A/1B-light 
chain 3 (LC3) and the degradation of p62, two key factors 
indicating activation of autophagy (Figure 3A). In fact, the 
mRNA level of MAP1LC3A was significantly increased 
in both A375p and A2058 cells exposed to PLX (Figure 
3B). Functionally, LC3 puncta corresponding to LC3-
labelled autophagosomes were considerably enriched in 
PLX-treated melanoma cells (Figures 3C, S3B), which 
was further demonstrated by the examination of labeled 
autophagosomes with electron microscopy (Supplementary 
Figure S3C). Pharmacological inhibition of autophagy 
by chloroquine (CQ) robustly abolished PLX-triggered 
MerTK overexpression (Figure 3D). Similarly, blocking 
the assembly of the autophagic initiating complex or the 
formation of autophagosomes by knocking down ULK1 
or ATG7, respectively, vigorously suppressed both basal 
and induced MerTK expression (Figures 3E, S3D). As 
inhibition of autophagy at three different stages could 
suppress MerTK expression (Supplementary Figure 
S3E), these data illustrated a stringent dependence of 
MerTK upregulation on autophagy. A short treatment 
(24 h) of A375p cells pre-incubated with PLX (thus 
overexpressing MerTK) with CQ rapidly decreased 
MerTK levels (Supplementary Figure S3F), indicating 
that autophagy actively participates in the regulation of 
MerTK. In contrast, MerTK deficiency did not affect p62 
degradation (Supplementary Figure S3G), demonstrating 
that the MerTK pathway is signaling downstream of 
autophagy. Simultaneous inhibition of mutant BRAF 
and autophagy efficiently induced caspase 3 cleavage in 
7 melanoma cell lines (Figure 3F), which mimicked the 
phenotype of cells with loss of MerTK when exposed to 
BRAFi stress as previously observed (Figure 2C). These 
data demonstrated a pro-survival role of the autophagy/
MerTK axis that desensitized melanoma cells to BRAFi-
triggered apoptosis.
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Figure 2: MerTK promotes melanoma cell survival and tumor formation. A., Endogenous MERTK was knocked down by 
shRNA in three melanoma cell lines (expressing BRAFV600E and different basal level of MerTK: A375p, low; A2058, medium; SKMel100, 
high). Optimization of shRNA was performed (Figure S2F). 500 cells per well were grown on 6-well plates incubated with vemurafenib (1 
or 2 μM, equal volume of DMSO was used as control) for 12 or 24 days and stained with crystal violet. The control of MerTK depletion was 
shown by western blot. The size of the colony was measured with ImageJ (see also Figure S2H). Each sample was prepared in triplicates. 
B., FACS analysis of apoptotic potential (represented by Annexin V-positive cells) of A375p and A2058 cells with depleted MerTK in 
presence/absence of vemurafenib. P1 = 0.004; P2 = 0.227; P3 = 4.43E-06; P4 = 1.8E-05; P5 = 0.015; P6 = 0.482; P7 = 0.6E-03; P8 = 1.5E-
04. C., A375p, A2058 and SKMel100 cells with MerTK-depletion were treated with vemurafenib (1 μM) for 3 days and the level of cleaved 
caspase 3 was determined. D., Growth of xenograft tumours derived from inoculated A375p melanoma cells with MERTK knockdown. 
16~18 mice per group were subcutaneously injected with A375p_shCTRL or A375p_shMERTK. The tumour size was measured twice 
a week. The resected xenograft tumours represented the size on day 41(week 6 post-injection). E., Statistical comparison of tumour size 
between A375p_shCTRL (square) or A375p_shMERTK (triangle) at two time points: week 6 and week 8. Depletion of MerTK in the 
tumors was demonstrated by western blot. P value was calculated with GraphPad Prism.
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Figure 3: MerTK was stringently regulated by autophagy. A., The elevated autophagic activity following vemurafenib treatment 
(1 μM) was determined by increased LC3 cleavage and enhanced degradation of p62 at given time-points. Increased LC3 cleavage was 
determined by the ratio of LC3-II versus actin measured with ImageJ. B., Global increase of MAP1LC3A mRNA (encoding LC3) was 
measured by qPCR in A375p and A2058 cells treated with vemurafenib (1 μM) for 3 days. Each sample was measured in triplicates. C., 
GFP-LC3 puncta (representing autophagosomes) was determined in A375p and A2058 cells expressing GFP-LC3 treated with vemurafenib 
(1 μM) at indicated time-points. The number of GFP-labeled autophagosomes was counted under the microscope. Three independent 
transfection experiments were performed. P1 = 0.004; P2 = 0.0002. See also Figure S3B. D., Expression of MerTK and mTORC1 activity 
were investigated in melanoma cells treated with vemurafenib (1 μM, 3 days) and the pharmacological autophagy inhibitor Chloroquine 
(CQ, 30 μM, 3 days). Enriched LC3II fragments indicated defective lysosome-mediated degradation by CQ treatment. E., Determination 
of MerTK expression level in melanoma cells with transient depletion of autophagy initiating kinase ULK1 by siRNA for 3 days. F., 
Monitoring of apoptotic potential in 7 cell lines co-treated with PLX and CQ for 3 days. The level of cleaved caspase 3 was used to 
determine apoptosis. 
Oncotarget69210www.impactjournals.com/oncotarget
Autophagy-dependent regulation of MerTK is 
mediated by BRAFi-triggered deactivation of 
mTORC1
One of the best characterized signalosomes that 
regulate autophagy is mTORC1. mTORC1 anchors and 
deactivates the autophagic complex on its surface via 
mTOR-directed phosphorylation of ULK1, the central 
kinase assembling the autophagy-initiating complex 
[25]. To examine whether autophagy-mediated MerTK 
activation could be mediated by mTORC1, we exposed 
melanoma cells to the pharmacological allosteric inhibitor 
rapamycin. In a time-course-dependent manner, MerTK 
expression increased within 48 hours in the presence 
of 200 nM of rapamycin and this was associated with a 
decrease in mTORC1-dependent phosphorylation of S6K1 
(on Thr389) and 4EBP1 (on Ser65), as well as enhanced 
LC3 cleavage, indicating an enhancement of autophagy 
(Figure 4A). This is further demonstrated by increased 
functional assembly of autophagosomes in response to 
rapamycin (Figure 4B). Torin, an ATP-competitive mTOR 
inhibitor, could also moderately upregulate MerTK at 
low concentration (10 nM) in association with increased 
LC3 cleavage (Supplementary Figure S4A). Indeed, 
the phosphorylation level of both S6K and 4EBP1 was 
decreased in presence of PLX (Figure 4C), suggesting 
that inhibition of BRAFV600E in melanoma cells resulted 
in downregulation of mTORC1 activity, which was 
also reported in an independent study recently [26]. In 
agreement with the outcome of rapamycin treatment, 
disruption of mTORC1 by genetic depletion of its key 
component Raptor, but not Rictor, activated MerTK 
expression (Figure 4D) and enhanced autophagosome 
formation (Supplementary Figure S4B). Taken together, 
the impact of mTORC1-regulated autophagy/MerTK 
resulted from inhibition of hyperactive mutant BRAF-
driven MAPK signaling, indicating an interaction between 
these two signaling axes. In this context, mTORC1 
activation could be regulated via two potential routes: 
ERK-mediated enhancement of Raptor, or ERK-mediated 
inhibition of tuberous Sclerosis Complex 2 (TSC2), a 
native intracellular inhibitor that restrains mTORC1 
activation in vivo. In response to PLX treatment up to 
3 days in 6 melanoma cell lines, ERK-regulated TSC2 
phosphorylation is continuously reduced together with 
decreased phosphorylation of S6 on serine 235/236, 
indicating a functional release of TSC2 from ERK 
inhibition (Figure 4E), whereas the ERK-mediated Raptor 
phosphorylation is unchanged (data not shown). These 
data indicate that BRAFi triggers TSC2 activation that 
inhibits mTORC1, which leads to downstream signaling 
activation of autophagy/MerTK.
MerTK is directly activated by epithelial-
mesenchymal transition (EMT) regulator Zeb2
Although the precise molecular mechanism 
was still unknown, several studies indicated that RTK 
activation in response to BRAFi in melanoma was 
possibly a transcriptional event [9]. This was confirmed 
in our hands since downregulation of MerTK by 
inhibition of autophagy was due to decreased MERTK 
transcription (Supplementary Figure S5A) but not to a 
change of protein stability (Supplementary Figure S5B) 
as reported during the regulation of retinal phagocytosis 
[27]. To explore the molecular details how MERTK was 
regulated, we analyzed the transcription factors that were 
co-upregulated in two melanoma cell lines (A375p and 
A2058) treated with PLX. Based on the mRNA fold-
change, the top 7 (out of 22) candidates were selected for 
evaluation. These 7 genes were transiently knocked down 
and the MERTK mRNA was measured by qPCR. When 
the mRNA of these 7 genes was targeted by individual 
siRNAs (Supplementary Figure S5C), the MERTK level 
was significantly affected by SNAI2 and ZEB2 depletion, 
but only mildly reduced with IRF9 knockdown compared 
to control (Figure 5A, red bar). This influence of the 
depletion of SNAI2 and ZEB2, rather than IRF9, was 
also reflected at the protein level (Figure 5A, red stars). 
However, unlike Zeb2, in presence of PLX, overexpression 
of Irf9 and Snai2 did not enhance MerTK expression 
(Figure 5B). Similarly, expression of Irf9 failed to increase 
MERTK-promoter-driven luciferase activity, which was 
significantly promoted with Zeb2 expression but only 
slightly with Snai2 expression (Figure 5C), implying that 
Zeb2 may be a major regulator of the MERTK promoter. 
Indeed, PLX-treatment induced Zeb2 accumulation in the 
nucleus (Figure 5D). Transient downregulation of Zeb2 
with either of two distinct pairs of siRNAs effectively 
blocked BRAFi-induced MerTK expression (Figure 5E). 
The promoter region of MERTK contains a conserved 
E-box (E1) close to the transcription start that represents 
a potential binding site for E-box-binding proteins such 
as Zeb2. Within 1kb upstream of transcription start, 
there are also other E-boxes on both human and mouse 
promoters of MERTK. To investigate if Zeb2 can bind 
to these core enhancers, we performed a chromatin 
immunoprecipitation (ChIP) assay using overexpressed 
human Zeb2 in A375p melanoma cells. In the presence 
of PLX, Zeb2 preferentially binds to the proximal 
promoter region of human MERTK harbouring E-box 1 
(E1), although mild binding to the E-box 2 (E2) could 
also be observed to a certain extent (Figure 5F). These 
results indicate that Zeb2 is capable of transcriptionally 
upregulating MERTK via direct binding to its promoter, 
whose activation controls MerTK expression in melanoma 
cells upon inhibition of mutant BRAF. In agreement with 
the in vitro studies, in the four paired human melanomas 
where MerTK is overexpressed post-vemurafenib therapy 
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Figure 4: Vemurafenib upregulates MerTK through the mTORC1/autophagy signaling axis. A., A375p and A2058 cells 
were treated with 200 nM of rapamycin and the activities of mTORC1 (S6K_pT389/4EBP1_pS65) and autophagy (LC3 cleavage) were 
determined at the indicated time-points. B., Quantification of GFP-LC3 puncta (labeled autophagosomes) in the presence of rapamycin 
(200 nM), vemurafenib (1 μM), or serum starvation (STA). GFP-LC3 was transiently expressed for 3 days and the treatment was 
administered for 2 days. C., A375p and A2058 cells were treated with vemurafenib (1 μM) and the mTORC1 activity was determined by 
the phosphorylation level of its substrates S6K1 and 4EBP1 at the given time-points. D., MerTK expression was determined in A375p and 
A2058 with knockdown of RPTOR and RICTOR (NS, non-specific). E., Phosphorylation status of endogenous mTORC1 inhibitor TSC2 
was examined in 6 melanoma cell lines treated with vemurafenib (1 μM) at indicated time-points. 
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Figure 5: MerTK is a direct downstream target of Zeb2. A., 7 transcription factors (TFs) that were upregulated in vemurafenib-
treated A375p and A2058 melanoma cells were transiently knocked down and the level of MERTK mRNA was analyzed by qPCR (see 
also Figure S5C). The decreased MerTK expression at protein level was highlighted with red stars. B, Detection of MerTK expression 
in A375p cells expressing recombinant Zeb2, IRF9 and Snai2 after a 3 day course of vemurafenib therapy. C., Luciferase reporter assay 
of transcriptional activity of Zeb2, IRF9 and Snai2 on MERTK promoter. Individual E-boxes located within MERTK promoter region 
(1kb) were highlighted in black squares and the corresponding sequences were listed. P value was calculated with student t-test. D., 
Immunostaining of endogenous Zeb2 in A375p cells treated with vemurafenib. Nuclear translocation of Zeb2 was counted in A375p cells 
treated with either vemurafenib or dabrafenib (1 μM). E., Detection of MerTK expression in A375p cells expressing two different pairs 
of ZEB2 siRNA in the presence of vemurafenib. F., Chromatin was immunoprecipitated with the indicated antibodies [immunoglobulin 
G (IgG) as negative control] in A375p cells expressing recombinant Zeb2. Corresponding amplified DNA fragments were indicated in 
the promoter region of MERTK (the primers used are listed in supplementary Table S1). G., Immunohistochemical staining of Zeb2 in 
two paired human melanomas before and after vemurafenib therapy. Purple staining indicates Zeb2. Note: the dark brown is not from the 
staining but due to the natural pigment melanin. 
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(Figure 1D), nuclear accumulation of Zeb2 is broadly 
present in resistant tumors (Figure 5G). However, the 
brain metastases from patient 8 showed equally high 
levels of Zeb2 before treatment compared with lymph 
node metastases after treatment, while MerTK was only 
mildly detectable (Supplementary Figure S5E). In patient 
7, although MerTK was indistinguishably overexpressed 
in both pre- and post-vemurafenib treated tumors, the 
Zeb2 level was significantly higher in relapsed brain 
metastases after treatment (Supplementary Figure S5F). 
These observations suggest that except for Zeb2, MerTK 
is possibly regulated by other transcriptional events; 
vice versa, Zeb2 may transcriptionally regulate other 
downstream targets to confer resistance.
Inhibition of autophagy/MerTK overcomes 
BRAFi-induced resistance in a xenograft model
Due to tumour relapse in vivo (Figure 2E), mice 
injected with MerTK-depleted A375p melanoma cells did 
not have longer survival (Supplementary Figure S6A), and 
isolated CQ-treatment did not induce tumour regression 
(Figure 6A). In contrast, PLX-treatment (starting from 
day 34) potently inhibited tumor growth during the 
exponential growth phase (day 34~60), although the 
tumours started to re-grow when the mice were still 
under daily PLX treatment (day 60~97) (Supplementary 
Figure S6B). The re-growth phase likely reflected in vivo 
resistance to vemurafenib that subsequently resulted in 
regained tumor growth. Thus, the tumor load of PLX-
treated mice was similar to that of mice treated with 
the vehicle or CQ alone (Supplementary Figure S6C). 
However, combined treatment with CQ and PLX showed 
a significantly improved anti-tumor activity over single 
treatment with PLX, even during the acute treatment for 
14 days (Supplementary Figure S6D). Under the same 
condition, the mice bearing MerTK-depleted tumours 
responded to BRAFi better than control mice bearing 
MerTK-expressing tumours after the treatment was 
stopped for 2 weeks (P1, day 60), but the response was 
lost after 4 weeks (P2, day 75) (Figure 6B), indicating that 
MerTK depletion at early time point potentially sensitized 
tumour response to vemurafenib in vivo. In order to 
evaluate long-term effect of MerTK depletion combined 
with vemurafenib treatment, we treated the mice bearing 
MerTK-deficient tumours with PLX for 8 weeks once 
daily. Long-term treatment with PLX and CQ abolished 
tumour regrowth compared with single treatment with 
PLX, which was pheno-copied by single PLX treatment 
combined with MerTK depletion (Figures 6C, S6B). The 
survival rate of mice bearing deficient MerTK treated with 
PLX was 100% at day 60, and ~50% at day 97 in the long-
term treatment, which was similar to the combinatorial 
treatment with CQ and PLX (~70%) in mice with intact 
MerTK (Figure 6D). In contrast, although prolonged 
monotherapy with PLX improved mouse survival (~55% 
on day 75) compared with short-term treatment (~15% 
on day 75, Figure 6B), no mouse survived beyond day 
97. These data demonstrated that MerTK overexpression 
can reduce the response of tumors to vemurafenib by 
protecting melanoma cells from environmental stress-
induced apoptosis. In fact, PLX treatment vigorously 
induced MerTK expression in xenograft tumours, which 
was robustly inhibited upon inhibition of autophagy with 
CQ (Figure 6E). Thus, co-targeting BRAFV600E and MerTK 
may substantially reduce tumour burden in mice, which 
pheno-copied the outcome of dual-inhibition of BRAFV600E 
and autophagy. 
DISCUSSION
The major challenge in clinical cancer therapy is 
drug-induced resistance that leads to unresponsiveness of 
tumor cells to a pharmacologically stressed environment 
[28, 29]. Hyperactivation of protective cellular signaling 
pathways, such as RTKs, PI3K/Akt, MAPK and 
autophagy, is almost universally observed in clinical 
cancer therapy. These protective signaling pathways are 
responsible for the occurrence of cancer resistance and 
relapse. The mechanisms of resistance have remained 
somewhat elusive [30]. Although recent studies revealed 
that reactivation of RTKs was one of the major drivers of 
resistance against BRAF inhibitors, little is known how 
this resistance is mechanistically modulated. In addition, 
although autophagy is required for cell survival [13, 31] 
and clinical studies confirm its global activation in tumors 
[32], isolated pharmacological suppression of autophagy 
did not meet success in clinical trials. Similarly, targeting 
of mTORC1 by rapalogs in cancers also induced rapid 
clinical resistance, whose mechanisms are currently under 
extensive investigation [33]. 
Our data highlight a novel mechanism of 
mTORC1/autophagy/MerTK-mediated resistance to 
BRAFi in melanoma harbouring BRAFV600E mutation 
(Supplementary Figure S6E). Unlike BRAFi, MEKi such 
as trametinib did not affect MerTK in tested cell lines 
with acquired resistance to trametinib (Supplementary 
Figure S1J). Importantly, trametinib did not block MerTK 
expression in BRAFi-resistant A375R cells, or in A375R 
with acquired resistance to both BRAFi and MEKi 
(A375R2) (Supplementary Figure S1J). Interestingly, this 
observation in established cell lines could be confirmed in 
biopsies from BRAFi/MEKi resistant human melanomas 
(Figure 1E), although more clinical melanomas with 
acquired resistance to combined BRAFi+MEKi should be 
examined. Nevertheless, our data not only demonstrates a 
stringent control of MerTK expression as a consequence 
of BRAF inhibition, but also hints at a potential role of 
MerTK as a mediator of resistance against combination 
therapy. Being the core machinery of host defense and 
survival, phagocytosis requires MerTK activation [34, 35] 
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Figure 6: Combined inhibition of mutant BRAF and autophagy/MerTK overcomes resistance to vemurafenib therapy. 
A., Survival analysis of mice inoculated with A375p_shCTRL cells and treated with vehicle or CQ (twice a week). B., Survival analysis of 
nude mice inoculated with A375p_shCTRL or A375p_shMERTK cells and treated with PLX for 14 days (acute treatment). Loss of MerTK 
improved animal survival before day 60 (P1 = 0.04) but this effect was lost on day 80 (P2 = 0.79). C., Growth curve of xenograft tumours 
in mice treated with PLX, PLX+CQ and PLX+shMerTK. The treatment started on day 34 and stopped on day 97. The tumour size was 
measured twice a week. Each group contained 9~10 mice. D., Kaplan-Meier survival analysis of nude mice injected with A375p_shCTRL 
or A375p_shMERTK and treated with PLX or Combo (CQ + PLX). Daily treatment started on day 34 (when the tumour volume was 
between 0.15 ~ 0.3 cm3) and stopped on day 97. The mice were necropsied when the tumor volume reached ~ 1 cm3. Each group contained 
8~10 mice. E., Analysis of MerTK expression in the xenograft tumours treated with PLX or combo (PLX+CQ). See also Figure 2E.
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and cross-talks to autophagy [36, 37], another metabolic 
and homeostatic regulating machinery adopted by cancer 
cells to improve their fitness [38]. In line with recent 
studies [20, 39], MerTK is emerging as an important 
regulator in tumorigenesis and metastasis, possibly 
playing a unique role at the crossroads between tumour 
cells and the host immune system. 
In presence of BRAFi, Zeb2 is significantly 
activated in melanoma cells. Zeb2 is a member of the 
δEF-1 protein family containing a homeodomain flanked 
by highly conserved zinc finger clusters at both termini 
[40]. During embryogenesis, genetic depletion of Zeb2 
leads to impaired mouse embryo development from E8.5, 
associated with early arrest of cranial neural crest cell 
migration and absence of neural crest cells [41]. This is 
a typical phenotype resulting from a defective function of 
EMT regulators such as Twist, Snai1/2, Zeb1/2 and E47 
[42]. Mechanistically, these EMT-driving transcription 
factors are activated in response to a variety of stimuli 
and subsequently lead to cell reprogramming [43] through 
mediating signaling crosstalk among different oncogenic 
pathways such as TGFβ [44, 45] and Notch [46], and 
significantly contribute to drug resistance in clinical 
cancer therapy [47]. However, in melanomas harbouring 
mutant BRAF, Zeb2 is dynamically switched on/off 
and inversely associated with MAPK activation [48]. In 
agreement with previous observations, our data showed 
reactivation of Zeb2 in response to BRAFi and consequent 
overexpression of MerTK. Thus, in the context of mutant 
BRAF inhibition in melanoma, the activation of Zeb2/
MerTK signaling plays an important role in mediating 
cancer cell survival and resistance. Interestingly, the Zeb2-
associated overexpression of MerTK was not observed in 
two paired melanomas (Supplementary Figures S5E and 
S5F). Although further quantitative analysis is needed, it 
seems that when high levels of MerTK are present before 
treatment starts, the tumor cells may take advantage of 
other mechanisms to survive BRAF or combined BRAF/
MEK blockade. 
Despite various investigated underlying 
mechanisms, including reactivation of the PI3K/Akt 
through a feedback loop, the parallel activation of MAPK 
axis, and Myc-driven oncogenesis, our data reveal that 
autophagy-regulated MerTK is crucially involved in 
promoting melanoma cell survival to resist BRAFV600E 
inhibition. This was confirmed by functional inhibition of 
the mTORC1 activity, as well as blockage of autophagy at 
different stages. Although autophagy has been considered 
a druggable target in cancer therapy, in agreement with 
previous in vivo studies [49], we showed that CQ treatment 
had no overall impact on A375p-xenograft tumour 
regression in mouse model and current clinical results are 
also disappointing. To a certain extent this is consistent 
with our observations that MerTK depletion (partly 
mimicking the consequence of autophagy inhibition in our 
model) delayed tumour formation but was not sufficient 
to block tumorigenicity, although other mechanisms could 
also be involved (Supplementary Figure S1I, patient 5). 
Nevertheless, co-inhibition of BRAFV600E with MerTK or 
autophagy remarkably improved progression-free survival. 
Interestingly, a recent study demonstrated that inhibition of 
autophagy may overcome BRAFi-induced resistance [50], 
and a combinatorial inhibition of mTOR and autophagy in 
a clinical phase I trial in patients with advanced melanoma 
patients has shown improvement of anti-tumor activity 
[51]. Therefore, we propose that simultaneous targeting 
of BRAFV600E and autophagy/MerTK signaling axes is 
a rational strategy for overcoming resistance to BRAF 
inhibitors in melanoma. 
MATERIALS AND METHODS
In vivo studies of drug inhibition
0A375 melanoma cells and its derivatives were 
subcutaneously injected into nude mice (Harlan France). 
PLX-4720 (stocked in DMSO and diluted in PBS 
containing 1% methylcellulose and 0.2% Tween 80) was 
administered orally at 45 mg/kg body weight daily [52]. 
CQ (dissolved in 0.9% NaCl) was injected twice a week 
at 50 mg/kg body weight [49]. The compounds were 
freshly prepared before treatment. The treatments started 
when flank tumours reached ~150 mm3. In the short-term 
experiment, the tumour-bearing mice were treated daily 
from day 31 for 14 days (day 31~45), following drug-free 
maintenance under standard conditions for additional 5 
weeks (day 46~80). In the experiment investigating long-
term therapy, the daily treatment with PLX started on day 
34 and ended on day 97. CQ was injected twice a week. 
Each group contained 8~10 mice and the tumours were 
resected when the volume reached ~1 cm3 (in accordance 
to Swiss Animal Protection Ordinance). The survival data 
and P value were presented with GraphPad Prism. See also 
supplemental methods.
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